Table 3.
Dose Reductions
| Patient | Assigned Selumetinib Dose (mg/m2/Dose BID) | Course when the Reduction Occurred | Reduced Selumetinib Dose (mg/m2/Dose BID) | Reason for Dose Reduction |
|---|---|---|---|---|
| 1 | 25 | 7 | 20 | Grade 4 CPK elevation |
| 25 | 9 | 15 | Grade 3 CPK elevation | |
| 2 | 25 | 3 | 20 | Grade 3 CPK elevation |
| 3 | 25 | 1 | 20 | Grade 3 hyponatremia |
| 25 | 23 | 15 | Grade 3 CPK elevation | |
| 4 | 25 | 2 | 20 | Grade 3 mucositis |
| 25 | 9 | 15 | Grade 3 CPK elevation | |
| 5 | 25 | 2 | 20 | Grade 4 CPK elevation |
| 25 | 6 | 15 | Grade 3 CPK elevation | |
| 6 | 25 | 6 | 20 | Grade 2 intolerable acneiform rash |
| 7 | 25 | 1 | 20 | Grade 3 abdominal pain |
| 25 | 13 | 15 | Grade 3 skin ulceration | |
| 8 | 25 | 2 | 20 | Grade 4 CPK elevation |
| 9 | 25 | 13 | 20 | Grade3 skin rash |
| 10 | 25 | 2 | 20 | Grade 2 intolerable rash |
| 11 | 25 | 2 | 20 | Ejection fraction decrease requiring drug hold for >7 days |
Abbreviation: CPK, creatine phosphokinase.